An interventional study of tACS or multisensory stimulation in Primary Progressive Aphasia, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Aphasia, Primary Progressive with a site in United States — 20 open to participants now, 24 under way, none of them phase 3. Aphasia, Primary Progressive · United States.
Among the 51 studies in Aphasia, Primary Progressive with a site in United States, this one is the 26th largest by planned enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2026, is one of 31 with no phase, reaches primary completion later than 21 of the 23 other live ones, and was the 50th registered.
77 studies on the registry are indexed under Aphasia, Primary Progressive; 28 are open to participants now.
Browse Aphasia, Primary Progressive studies →20 of the 51 studies in Aphasia, Primary Progressive with a site in United States are open now. Recruiting first, the newest first:
Maya Henry · Sites in United States
Ages 40+
Maya Henry · Sites in United States
Ages 40+
University of Pennsylvania · Sites in United States
Ages 18+ · Healthy volunteers
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
University of Missouri-Columbia · Sites in United States
Ages 50+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 24 Aphasia, Primary Progressive studies recruiting now, 13 (54%) set no upper age limit and 1 (4%) stops at 75 or younger; 1 takes children under 18; 10 take healthy volunteers.
This study: 45 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 6 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 30 across 60 interventional studies indexed under Aphasia, Primary Progressive.
Median enrollment 30 across the 43 interventional studies, 170 across the 8 observational. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 51 have an industry lead sponsor. The 10 most frequent:
Medical College of Wisconsin is the lead sponsor of 550 studies on the registry; 123 are open to participants now.
Of its 76 completed or terminated interventional studies of FDA-regulated products, 58 (76%) have results posted.
Medical College of Wisconsin has 2 studies filed under Aphasia, Primary Progressive — fewer than ten, so there is no comparison to draw.
10 of the studies in Aphasia, Primary Progressive with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06066710University of Missouri-ColumbiaPropranolol in Primary Progressive Aphasia | 2026-12 |
| NCT04920318University of ArizonaEnhancing Language Function in Primary Progressive Aphasia | 2026-12-30 |
| NCT00537004Northwestern UniversityLanguage in Primary Progressive Aphasia | 2027-04 |
| NCT06064890AviadoBio LtdA Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN) | 2027-04-01 |
| NCT05368350The University of Texas at DallasTreating Primary Progressive Aphasia and Apraxia of Speech Using Non-invasive Brain Stimulation | 2027-04-16 |
Add all 10 to your calendar (.ics) → With an account.
Among the 51 studies in Aphasia, Primary Progressive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this project is to investigate whether transcranial electrical stimulation and sensory stimulation affect language outcomes in individuals with primary progressive aphasia (PPA). The main questions it aims to answer are:
Does transcranial alternating current stimulation (tACS) affect verbal short-term memory (STM) in individuals with PPA? Does a single session of multisensory stimulation affect verbal STM in individuals with PPA? Researchers will compare active tACS to sham tACS (a fake stimulation condition) to see if active tACS improves verbal STM. Researchers will compare pre-multisensory stimulation to post-stimulation performance to see if multisensory stimulation improves verbal STM.
Participants will:
Undergo EEG, MRI (anatomical and functional) May complete a cognitive exam Undergo tACS over 3 separate sessions Undergo multisensory stimulation Complete language tasks before, during and/or after stimulation
The primary objective of the current project is to examine the effects of tACS and multisensory stimulation on verbal STM outcomes in individuals with PPA. The selection of parameters will be guided on the basis of oscillatory brain activity using language task-based or task-free EEG paradigms. Neuroimaging (MRI and functional MRI) will guide spatial targets of tACS. A secondary objective is to explore sources of individual variability in response to stimulation and whether these factors could offer insight into disease progression. This proof-of-concept, pilot project will generate essential preliminary data to help refine hypotheses for future clinical trials aimed at assessing the efficacy of these intervention strategies in predicting and treating (as in delaying) disease progression.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants in a within-subject design will receive high-Definition-tACS, delivered via a battery operated alternating current stimulator (Soterix) using two center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with frequencies ranging from 4-40Hz for 20-minutes with 2 milliampere (mA) peak-to-peak intensity. For sham stimulation, tACS is turned off after the first 30 seconds. All participants will receive light and/or sound flicker stimulation using an off-the-shelf app for 20 minutes.
Device: tACS or multisensory stimulation
Active or sham tACS Light and/or sound flickers
Changes in STM capacity assessed using a verbal STM task
Improvement in STM capacity with in-phase tACS and worsening of STM capacity with anti-phase tACS compared to sham tACS
Time frame: Changes monitored over pre, during and immediately after 20 minutes of tACS
Changes in STM capacity with multisensory stimulation using a verbal STM task
Improvement in STM capacity post-stimulation compared to pre-stimulation
Time frame: Changes monitored pre and immediately after 20 minutes of stimulation
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for May 2031, 59 months after the start.
Of 38 non-industry interventional studies with no phase under Aphasia, Primary Progressive, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's planned 59 months is above that.
Counting every sponsor, half of 38 studies reached it within 40 months; a quarter within 26 and three quarters within 59.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aphasia, Primary Progressive →
Medical College of Wisconsin →